Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease

Background 82-Rubidium-Positron emission tomography myocardial perfusion imaging (Rb-PET-MPI) offers higher diagnostic performance for the detection of myocardial ischemia compared to Tc-SPECT-MPI. The aim of this economic evaluation was to perform a cost-effectiveness analysis of Rb-PET-MPI versus Tc-SPECT-MPI in patients with suspected myocardial ischemia according to pretest probabilities (PTP) of obstructive coronary artery disease based on the results of the RUBIS Trial.Methods Costs and effectiveness were calculated for all patients over 1 year and an incremental analysis of differences in costs and effectiveness in terms of diagnostic accuracy was performed. The uncertainty of the results was estimated using bootstrap. The analysis was conducted from the perspective of the French health care system with a time horizon of 12 months.Results The average cost of a Rb-PET-MPI-based strategy for the detection of myocardial ischemia was euro219 lower than a SPECT-MPI-based strategy (euro1192 (& PLUSMN; 1834) vs euro973 (+/- 1939), p < 0.01). The one-year incremental cost-effectiveness ratio was negative: - euro2730 (money saved per additional accurate diagnosis) in patients presenting PTP > 15% for the Rb-PET-MPI vs. Tc-SPECT-MPI strategy. Analysis of the joint distribution of costs and outcomes found that the Rb-PET-MPI strategy had a 92% probability to be dominant (cost-saving and outcome-improving).Conclusions Rb-PET-MPI is cost-effective compared to Tc-SPECT-MPI for the detection of myocardial ischemia in patients with PTP > 15% of obstructive coronary artery disease.

Automated summary

This study evaluated the cost-effectiveness of Rb-PET-MPI compared to Tc-SPECT-MPI for detecting myocardial ischemia, and the results showed that Rb-PET-MPI was a cost-saving and outcome-improving option for patients with PTP > 15%.